KRAS and cancer: Even though it has been more than 30 years following the discovery of the role of KRAS in transforming cells and in driving cancer growth and development, there are no drugs in this current moment targeting the activating mutations of KRAS or selectively down-regulating KRAS mRNA and proteins, neither are there ones inhibiting downstream effector pathways in clinical trials.